Inmune Bio, Inc. (INMB): Insider Trading, Congress Trades & Research | Tormere

INMB

$1.32-4.35%visit website

Inmune Bio, Inc.

Market Cap

$37M

Live price × SEC shares (Aug 6, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.98

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

1.8

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	0.00	0.00
Research & development	4,887	2,329	3,641
Total operating expenses	7,433	5,474	5,812	1,476	20,195
Operating income	(7,433)	(5,474)	(5,812)	(1,476)	(20,195)
Net income	(6,472)	(5,264)	(5,407)	(1,273)	(18,416)
EPS (basic) ($)	(0.24)		(0.20)	(0.05)	(0.62)
EPS (diluted) ($)	(0.24)		(0.20)	(0.05)	(0.62)
Weighted avg. shares (basic)	26,585		26,585	26,719
Weighted avg. shares (diluted)	26,585		26,585	26,719

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 6, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 30 more quarters, back to Mar 2018, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

No Form 4 transactions on record.

Recent News

INmune Bio (INMB.US) will release its financial report after market close on November 5.

Moomoo · 2026-10-31

INMB 8-K & SEC Filings

Yahoo Finance · 2026-10-30

INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th

Yahoo · 2026-10-29

Third-quarter results and a corporate update are on INmune Bio's Nov. 5 call.

Stock Titan · 2026-10-29

INmune Bio Raises $4.5 Million in Stock Offering With Warrants

TradingView · 2026-10-29

INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement

Yahoo · 2026-10-28

INmune Bio Is A High-Potential Opportunity, But Here's Why I'm Waiting (NASDAQ:INMB)

Seeking Alpha · 2026-10-23

Manufacturing Progress Gives INmune Bio a Clearer UK Filing Path for Ebstrocel

Yahoo · 2026-10-21

INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027

Yahoo · 2026-10-21

INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar

Yahoo · 2026-10-21

INmune Bio Submits Final Pre-Marketing Authorization Application Package To UK MHRA For Ebstrocel For Recessive Dystrophic Epidermolysis Bullosa; Expects Full MAA Submission In Early February 2027, With Potential UK Approval In Mid-2027; Has Engaged U.S. Regulatory Advisors With Rare Disease Expertise To Prepare And Submit A Type B Meeting Request To FDA

Benzinga · 2026-10-21

Can Quantum Computing (QUBT) Be A Bargain As Its INmune Bio Deal Opens Biopharma?

Yahoo · 2026-10-16

QCi and INmune Bio partner to study XPro in Alzheimer’s

Yahoo · 2026-10-15

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™

Yahoo · 2026-10-14

INmune Bio And Quantum Computing Inc. Partner To Use Quantum AI To Identify New Treatment Applications For Alzheimer’s Drug XPro

Benzinga · 2026-10-14

Informational purposes only, not investment advice.

Corporate Events (8-K)

1 filing in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Oct 29, 2026 accepted 7:40 AM ET	1.01Material agreement3.02Unregistered equity sale7.01Reg FD disclosure	Document SEC ↗